O. Reg. 95/23: GENERAL
filed May 15, 2023 under Pharmacy Act, 1991, S.O. 1991, c. 36
Skip to contentontario regulation 95/23
made under the
Pharmacy Act, 1991
Made: April 4, 2023
Approved: May 11, 2023
Filed: May 15, 2023
Published on e-Laws: May 15, 2023
Published in The Ontario Gazette: June 3, 2023
Amending O. Reg. 202/94
(General)
1. (1) Paragraph 1 of subsection 34 (3) of Ontario Regulation 202/94 is revoked and the following substituted:
1. Before performing the act, the member must receive an informed consent from the patient or the patient’s authorized agent.
(2) Subsection 34 (3) of the Regulation is amended by adding the following paragraphs:
7. Where administering a substance specified in Schedule 1 by injection to a patient through an established central or peripheral venous access device, the member must only do so in collaboration with a member of the College of Nurses of Ontario who is a registered nurse in the extended class or a member of the College of Physicians and Surgeons of Ontario.
8. Where the act is performed for a purpose other than that of patient education or demonstration the member must, within a reasonable time after performing the act, notify the following persons that the member performed the act, and provide details respecting the act:
i. The prescriber, if any, of the substance that was administered.
ii. The patient’s primary care provider, where the member knows that the patient has such a care provider other than the prescriber.
(3) Section 34 of the Regulation is amended by adding the following subsection:
(3.1) Where a limitation or a route of administration is indicated with respect to a substance listed in Schedule 1, a member shall only administer the substance in compliance with the limitation and in accordance with the route of administration specified.
2. Schedules 1 and 2 to the Regulation are revoked and the following substituted:
Schedule 1
Injected Substances
Analgesics and Antipyretics
Codeine — For patient education and demonstration only
Hydromorphone — For patient education and demonstration only
Morphine — For patient education and demonstration only
Nalbuphine — For patient education and demonstration only
Antibacterials
Amikacin
Ampicillin
Cefazolin
Cefepime
Cefotaxime
Cefoxitin
Ceftazidime
Ceftriaxone
Clindamycin
Cloxacillin
Ertapenem
Gentamicin
Penicillin G
Anticholinergic Agents
Scopolamine — Must not be administered intravenously
Hyoscine — Must not be administered intravenously
Glycopyrrolate — Must not be administered intravenously
Anticoagulants
Dalteparin — Must not be administered intravenously
Danaparoid — Must not be administered intravenously
Enoxaparin — Must not be administered intravenously
Fondaparinux — Must not be administered intravenously
Heparin — For patient education and demonstration only
Nadroparin — Must not be administered intravenously
Tinazaparin
Antidiabetic Agents
Exenatide
Insulins
Liraglutide
Dulaglutide
Lixisenatide
Semaglutide
Antihemorrhagic Agents
Emicizumab
Antihistamines
Diphenhydramine — Only for monitoring and management of allergic reactions
Dimenhydrinate — Must not be administered intravenously
Antimigraine Agents
Sumatriptan
Erenumab
Antiparkinsonian Agents
Apomorphine
Benztropine
Antivirals
Enfuvirtide
Interferons
Peginterferon alfa-2a
Central Nervous System Agents, Miscellaneous
Inotersen
Complement Inhibitors
Icatibant
Lanadelumab
Disease-modifying Antirheumatic Drugs
Abatacept
Adalimumab
Anakinra
Etanercept
Golimumab — Must not be administered intravenously
Ustekinumab — Must not be administered intravenously
Methotrexate — Must not be administered intravenously
Sarilumab
Tocilizumab — Must not be administered intravenously
Enzymes
Asfotase Alfa
GI Drugs, Miscellaneous
Certolizumab Pegol
Methylnaltrexone
Gonadotropins and Antigonadotropins
Follitropin-alpha
Follitropin-beta
Follitropin-delta
Gonadotropin-chorionic
Gonadotropin-chorionic-alfa
Lutropin-alfa
Menotropins
Goserelin — For patient education and demonstration only
Triptorelin acetate
Gonadotropin-releasing Hormone Antagonists
Cetrorelix
Ganirelix
Heavy Metal Antagonists
Deferoxamine — For patient education and demonstration only
Hematopoietic Agents
Darbepoetin alfa — Must not be administered intravenously
Epoetin alfa — Must not be administered intravenously
Filgrastim — Must not be administered intravenously
Pegfilgrastim
Romiplostim — For patient education and demonstration only
Immunomodulatory Agents
Denosumab
Glatiramer
Interferon-Beta-1A
Interferon-Beta-1B
Natalizumab
Immunosuppressive Agents
Belimumab — Must not be administered intravenously
Mepolizumab
Miscellaneous Agents
Sterile Water for Injection (Diluent)
Sodium Chloride
Parathyroid
Calcitonin Salmon — For patient education and demonstration only
Teriparatide
Pituitary
Desmopressin — For patient education and demonstration only
Vasopressin — For patient education and demonstration only
Progestins
Medroxyprogesterone
Progesterone
Prokinetic Agents
Metoclopramide
Proprotein Convertase Subtilisin Kexin Type 9 (Pcsk9) Inhibitors
Alirocumab
Evolocuma
Psychotherapeutic Agents
Haloperidol — For patient education and demonstration only
Methotrimeprazine — For patient education and demonstration only
Respiratory Tract Agents
Omalizumab
Skin And Mucous Membrane Agents
Brodalumab
Dupilumab
Guselkumab
Ixekizumab
Risankizumab — Must not be administered intravenously
Secukinumab
Somatostatin Agonists and Antagonists
Pasireotide
Octreotide — Must not be administered intravenously
Lanreotide
Somatotropin Agonists and Antagonists
Somatropin
Pegvisomant
Tesamorelin
Sympatholytic (Adrenergic Blocking) Agents
Dihydroergotamine — Must not be administered intravenously
Vitamins
Cyanocobalamin
Folic Acid — Must not be administered intravenously
Pyridoxine — Must not be administered intravenously
Thiamine — Must not be administered intravenously
Ascorbic Acid — Must not be administered intravenously
Vitamin K
Schedule 2
Inhaled Substances
Anticholinergic Agents
Ipratropium
Tiotropium
Aclidinium
Glycopyrronium
Umeclidinium
Formoterol
Indacaterol
Olodaterol
Salbutamol
Salmeterol
Terbutaline
Vilanterol
Anti-infective Agents
Zanamivir
Levofloxacin
Tobramycin
Aztreonam
Autonomic Drugs, Miscellaneous
Nicotine
Eye, Ear, Nose and Throat (EENT) Preparations
Sodium Cromoglycate
Beclomethasone
Budesonide
Ciclesonide
Fluticasone
Mometasone
Miscellaneous Agents
Sodium chloride
Sterile water for inhalation
Respiratory Tract Agents
Acetylcysteine
Dornase alfa
Commencement
3. This Regulation comes into force on the later of July 1, 2023 and the day this Regulation is filed.
Made by:
Council of the Ontario College of Pharmacists:
Shenda Tanchak
Registrar and CEO
James Morrison
Board Chair
Date made: April 4, 2023